ARCELORMITTAL (MT.AS)

LU1598757687 - Common Stock

24.17  -0.14 (-0.58%)


Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to MT. MT was compared to 21 industry peers in the Metals & Mining industry. Both the profitability and financial health of MT have multiple concerns. MT is cheap, but on the other hand it scores bad on growth




Profitability

Profitability Rating

2

MT has a Profit Margin of 8.20%. This is comparable to the industry average of 8.20%.
The Piotroski-F score of MT is 5.00. This is a neutral score and indicates average health and profitability for MT.

MT's Return On Assets of 6.59% is worse than the rest of the industry. The industry average Return On Assets is 7.62%.
MT has a Return On Equity of 11.62%. This is below the industry average of 16.50%.
VS Industry

ROA (6.59%) VS Industry: 31% outperformed.

0.08
38.55

ROE (11.62%) VS Industry: 25% outperformed.

0.15
69.43

Profit Margin (8.2%) VS Industry: 46% outperformed.

0.24
40.12

Valuation

Valuation Rating

10

With a Price/Earnings Ratio of 3.25, the valuation of MT can be described as very cheap.
MT's Price/Earning Ratio is rather cheap when compared to the industry average which is at 7.01. MT is also cheaper than 87% of the companies in the same industry.
The Forward Price/Earnings Ratio of 5.13 indicates a rather cheap valuation of MT.
MT's low PEG Ratio, which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.

When comparing the current price to the book value of MT, it is valued rather cheaply. It is trading at 0.38 times its book value.
When comparing the price book ratio of MT to the average industry price book ratio of 1.19, MT is valued rather cheaply. MT is also cheaper than 89% of the companies listed in the same industry.
When comparing the Enterprise Value to EBITDA ratio of MT to the average industry ratio of 3.88, MT is valued rather cheaply.
VS Industry

Price/Earnings (3.25) VS Industry: 87% outperformed.

26.38
0.62

Price/Book (0.38) VS Industry: 89% outperformed.

2.61
0.31

Enterprise Value/ EBITDA (2.67) VS Industry: 68% outperformed.

27.15
0.01

Growth

Growth Rating

2

Measured over the past 5 years, MT shows a very strong growth in Earnings Per Share. The EPS has been growing by 21.56% on average per year.
MT shows a decrease in Revenue. In the last year, the revenue decreased by -6.94%.
The Revenue has been growing slightly by 3.06% on average over the past 5 years.
MT is expected to show a decrease in Revenue. In the coming 5 years, the Revenue will decrease by -3.63% yearly.

The earnings per share for MT have decreased strongly by -49.14% in the last year.
Based on estimates for the next 5 years, MT will show a very negative growth in Earnings Per Share. The EPS will decrease by -19.81% on average per year.
When comparing the EPS growth rate of the last years to the growth rate of the upcoming 5 years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming 5 years, we see that the growth is decreasing.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPS21.56% N/A -49.14% -60.96% -32.08% -19.81% N/A
Revenue3.06% 4.18% -6.94% -11.38% -6.48% -3.63% N/A

Health

Health Rating

2

When comparing the Debt to Equity Ratio of 0.16 to an average industry Debt to Equity of 0.21, MT is way less dependent on financing that its industry peers.
MT has a Current Ratio of 1.57. This is a normal value and indicates that MT is financially healthy and should not expect problems in meeting its short term obligations.
MT has a Piotroski-F score of 5.00. This indicates an average health and profitability for MT.

When comparing the Current Ratio of MT to the average industry Current Ratio of 1.82, MT is less able to pay its short term obligations than its industry peers. 85% of its industry peers have a better Current Ratio.
MT has a Quick Ratio of 1.57. This is a bad value and indicates that MT is not financially healthy enough and could expect problems in meeting its short term obligations.
When comparing the Quick Ratio of MT to the average industry Current Ratio of 1.10, MT is less able to pay its short term obligations than its industry peers. 85% of its industry peers have a better Quick Ratio.
VS Industry

Debt/Equity (0.16) VS Industry: 68% outperformed.

3.81
0.00

Quick Ratio (0.7) VS Industry: 15% outperformed.

0.33
2.58

Current Ratio (1.57) VS Industry: 15% outperformed.

0.41
2.66

Dividend

Dividend Rating

3

5.29% of the earnings are spent on dividend by MT. This is a low number and sustainable payout ratio.
With a Yearly Dividend Yield of 1.72%, MT has a reasonable but not impressive dividend return.
With a Dividend Yield of 1.72, MT pays less dividend than the industry average, which is at 3.68. 87% of the companies listed in the same industry pay a better dividend than MT!

MT's Dividend Yield is slightly below the S&P500 average, which is at 2.72.
The dividend of MT decreases each year by -9.69%.
MT's earnings and Dividend Rate are declining. This means the current dividend is most likely not sustainable.
VS Industry

Dividend Yield (1.72%) VS Industry: 13% outperformed.

0.39
16.41

ARCELORMITTAL

AMS:MT (5/29/2023, 5:35:15 PM)

24.17

-0.14 (-0.58%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryMetals & Mining
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap18.86B
Analysts80
Price Target34.83 (44.1%)
Dividend
Industry RankSector Rank
Dividend Yield 1.72%
Dividend Growth(5Y)-9.69%
DP5.29%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)214.11%
Min EPS beat(2)108.19%
Max EPS beat(2)320.03%
EPS beat(4)3
Avg EPS beat(4)102.82%
Min EPS beat(4)-25.21%
Max EPS beat(4)320.03%
Revenue beat(2)2
Avg Revenue beat(2)9.16%
Min Revenue beat(2)8.93%
Max Revenue beat(2)9.38%
Revenue beat(4)3
Avg Revenue beat(4)5.87%
Min Revenue beat(4)-2.33%
Max Revenue beat(4)9.38%
PT rev (1m)0%
PT rev (3m)5.91%
EPS NQ rev (1m)0%
EPS NQ rev (3m)4.17%
EPS NY rev (1m)0%
EPS NY rev (3m)22.11%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)19.47%
Revenue NY rev (1m)0%
Revenue NY rev (3m)13.6%
Valuation
Industry RankSector Rank
PE 3.25
Fwd PE 5.13
P/S 0.27
P/FCF 3.87
P/OCF 2.22
P/B 0.38
P/tB 0.41
EV/EBITDA 2.67
EPS(TTM)7.43
EY30.74%
EPS(NY)4.72
Fwd EY19.51%
FCF(TTM)6.25
FCFY25.85%
OCF(TTM)10.87
OCFY44.97%
SpS91.2
BVpS64.34
TBVpS58.35
PEG (NY)N/A
PEG (5Y)0.15
Profitability
Industry RankSector Rank
ROA 6.59%
ROE 11.62%
ROIC 8.3%
ROICexc 9.09%
ROICexgc 9.84%
OM 9.19%
PM 8.2%
GM 17.72%
ROICexgc(3y)13.91%
ROICexcg growth 3Y104.66%
ROICexcg growth 5Y17.96%
ROICexc(3y)12.89%
ROICexc growth 3Y105.3%
ROICexc growth 5Y18.33%
OM growth 3Y97.35%
OM growth 5Y15.11%
PM growth 3YN/A
PM growth 5Y11.86%
GM growth 3Y48.6%
GM growth 5Y10.2%
F-Score5
Asset Turnover0.8
Health
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF 2.19
Debt/EBITDA 1.2
Cap/Depr 151.27%
Profit Quality 83.55%
Current Ratio 1.57
Quick Ratio 0.7
Altman-Z N/A
F-Score5
WACC9%
ROIC/WACC1.09
Cap/Depr(3y)112.01%
Cap/Depr(5y)114.12%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
Growth
EPS 1Y-49.14%
EPS 3YN/A
EPS 5Y21.56%
EPS growth Q2Q-70.26%
EPS Next Y-60.96%
EPS Next 2Y-32.08%
EPS Next 3Y-19.81%
EPS Next 5YN/A
Revenue growth 1Y-6.94%
Revenue growth 3Y4.18%
Revenue growth 5Y3.06%
Revenue growth Q2Q-15.27%
Revenue Next Year-11.38%
Revenue Next 2Y-6.48%
Revenue Next 3Y-3.63%
Revenue Next 5YN/A
EBIT growth 1Y-62.54%
EBIT growth 3Y105.6%
EBIT growth 5Y18.63%
EBIT Next Year-33.27%
EBIT Next 3Y-10.08%
EBIT Next 5YN/A
FCF growth 1Y131.19%
FCF growth 3Y39.99%
FCF growth 5Y30.83%
OCF growth 1Y103.75%
OCF growth 3Y19.18%
OCF growth 5Y17.39%
Fundamental Stock Screener Links
Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the EuroNext

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the EuroNext

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the EuroNext

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the EuroNext